Clinical Trial Update: A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies [Phase 1]

View source ↗

Summary

Phase 1 trial of AUR106 in relapsed advanced malignancies has been terminated; the document provides a status update on this study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Esophageal Cancer
• Gastric Cancer
• Kidney Cancer
• Non-small Cell Lung Cancer
• Urothelial Carcinoma

Drugs mentioned

• AUR106

Snippet

Sponsor: Aurigene Discovery Technologies Limited | Conditions: Relapse, Advanced Malignant Neoplasm | Phase 1 | Status: TERMINATED